Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Revenue (2022 - 2025)

Historic Revenue for Century Therapeutics (IPSC) over the last 4 years, with Q1 2025 value amounting to $109.2 million.

  • Century Therapeutics' Revenue rose 1266771.93% to $109.2 million in Q1 2025 from the same period last year, while for Sep 2025 it was $113.3 million, marking a year-over-year increase of 412111.73%. This contributed to the annual value of $6.6 million for FY2024, which is 19480.98% up from last year.
  • Per Century Therapeutics' latest filing, its Revenue stood at $109.2 million for Q1 2025, which was up 1266771.93% from $4.2 million recorded in Q4 2024.
  • Century Therapeutics' Revenue's 5-year high stood at $109.2 million during Q1 2025, with a 5-year trough of $99000.0 in Q2 2023.
  • Its 4-year average for Revenue is $9.5 million, with a median of $855000.0 in 2024.
  • Its Revenue has fluctuated over the past 5 years, first crashed by 9334.53% in 2023, then skyrocketed by 1266771.93% in 2025.
  • Over the past 4 years, Century Therapeutics' Revenue (Quarter) stood at $521000.0 in 2022, then crashed by 48.56% to $268000.0 in 2023, then soared by 1457.09% to $4.2 million in 2024, then surged by 2515.96% to $109.2 million in 2025.
  • Its Revenue stands at $109.2 million for Q1 2025, versus $4.2 million for Q4 2024 and $791000.0 for Q3 2024.